The role of CXCL1/CXCR2 axis in neurological diseases
International Immunopharmacology · 2023-07 · 120 · 110330
DOI: 10.1016/j.intimp.2023.110330 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Immunopharmacology, 2023-07. Verfasst von Suli Jiang und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China. Hauptthemen laut MEDLINE: Pain, Nervous System Diseases. Die Arbeit wurde bisher 60-mal zitiert (Crossref) und nennt 146 Literaturangaben. Gefördert von: National Natural Science Foundation of China-Shandong Joint Fund for Marine Science Research Centers, Natural Science Foundation of Shandong Province.
Abstract (Originalsprache)
The C-X-C chemokine ligand (CXCL) 1 and its receptor C-X-C chemokine receptor (CXCR) 2 are widely expressed in the peripheral nervous systems (PNS) and central nervous systems (CNS) and are involved in the development of inflammation and pain after various nerve injuries. Once a nerve is damaged, it affects not only the neuron itself but also lesions elsewhere in its dominant site. After the CXCL1/CXCR2 axis is activated, multiple downstream pathways can be activated, such as c-Raf/MAPK/AP-1, p-PKC-μ/p-ILK/NLRP3, JAK2/STAT3, TAK1/NF-κB, etc. These pathways in turn mediate cellular motility state or cell migration. CXCR2 is expressed on the surface of neutrophils and monocytes/macrophages. These cells can be recruited to the lesion through the CXCL1/CXCR2 axis to participate in the inflammatory response. The expression of CXCR2 in neurons can activate some pathways in neurons through the CXCL1/CXCR2 axis, thereby causing damage to neurons. CXCR2 is also expressed in astrocytes, and when CXCR2 activated, it increases the number of astrocytes but impairs their function. Since inflammation can occur at almost any site of injury, elucidating the mechanism of CXCL1/CXCR2 axis' influence on inflammation may provide a favorable target for clinical treatment. Therefore, this article reviews the research progress of the CXCL1/CXCR2 axis in neurological diseases, aiming to provide a more meaningful theoretical basis for the treatment of neurological diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China.
- Department of Special Medicine, School of Basic Medical College, Qingdao University, Qingdao, Shandong 266071, PR China.
- Department of Immunology, Medical College of Qingdao University, Qingdao, Shandong 266071, PR China. Electronic address: zhangbei124@aliyun.com.
Förderung
- National Natural Science Foundation of China-Shandong Joint Fund for Marine Science Research Centers
- Natural Science Foundation of Shandong Province
Zitieren
APA
Jiang, S., Liang, J., Li, W., Wang, L., Song, M., Xu, S., Liu, G., Du, Q., Zhai, D., Tang, L., Yang, Y., Zhang, L., & Zhang, B. (2023). The role of CXCL1/CXCR2 axis in neurological diseases. International Immunopharmacology, 120, 110330. https://doi.org/10.1016/j.intimp.2023.110330
Vancouver
Jiang S, Liang J, Li W, Wang L, Song M, Xu S, et al. The role of CXCL1/CXCR2 axis in neurological diseases. International Immunopharmacology. 2023;120:110330. doi:10.1016/j.intimp.2023.110330
BibTeX
@article{Jiang2023,
author = {Jiang, Suli and Liang, Jie and Li, Wei and Wang, Luoyang and Song, Meiying and Xu, Shuo and Liu, Guixian and Du, Qiaochu and Zhai, Dongchang and Tang, Lei and Yang, Yanyan and Zhang, Li and Zhang, Bei},
title = {The role of CXCL1/CXCR2 axis in neurological diseases},
journal = {International Immunopharmacology},
year = {2023},
volume = {120},
pages = {110330},
doi = {10.1016/j.intimp.2023.110330}
}
EUVIMED